Passa al contenuto
Merck

Tracer metabolomics reveals the role of aldose reductase in glycosylation.

Cell reports. Medicine (2023-06-01)
Silvia Radenkovic, Anna N Ligezka, Sneha S Mokashi, Karen Driesen, Lynn Dukes-Rimsky, Graeme Preston, Luckio F Owuocha, Leila Sabbagh, Jehan Mousa, Christina Lam, Andrew Edmondson, Austin Larson, Matthew Schultz, Pieter Vermeersch, David Cassiman, Peter Witters, Lesa J Beamer, Tamas Kozicz, Heather Flanagan-Steet, Bart Ghesquière, Eva Morava
ABSTRACT

Abnormal polyol metabolism is predominantly associated with diabetes, where excess glucose is converted to sorbitol by aldose reductase (AR). Recently, abnormal polyol metabolism has been implicated in phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG) and an AR inhibitor, epalrestat, proposed as a potential therapy. Considering that the PMM2 enzyme is not directly involved in polyol metabolism, the increased polyol production and epalrestat's therapeutic mechanism in PMM2-CDG remained elusive. PMM2-CDG, caused by PMM2 deficiency, presents with depleted GDP-mannose and abnormal glycosylation. Here, we show that, apart from glycosylation abnormalities, PMM2 deficiency affects intracellular glucose flux, resulting in polyol increase. Targeting AR with epalrestat decreases polyols and increases GDP-mannose both in patient-derived fibroblasts and in pmm2 mutant zebrafish. Using tracer studies, we demonstrate that AR inhibition diverts glucose flux away from polyol production toward the synthesis of sugar nucleotides, and ultimately glycosylation. Finally, PMM2-CDG individuals treated with epalrestat show a clinical and biochemical improvement.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
HEPES, ≥99.5% (titration)
Sigma-Aldrich
Anti-AKR1B1 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution